Appropriatezza diagnostico-terapeutica in oncologia - Quaderni del ...

Neoplasie della mammella 3
LHRH agonists in Early Breast Cancer Overview
group. Use of luteinising-hormone-releasing hormoneagonists
as adjuvant treatment in premenopausal
patients with hormone-receptor-positive breast cancer:
a meta-analysis of individual patient data from randomised
adjuvant trials. Lancet 2007; 369: 1711-23
Lim HS, Ju Lee H, Seok Lee K, et al. Clinical implications
of CYP2D6 genotypes predictive of tamoxifen
pharmacokinetics in metastatic breast cancer. J Clin
Oncol 2007; 25: 3837-45
Mamounas E, Jeong J-H, Wickerham L, et al. Benefit
from exemestane as extended adjuvant therapy after 5
years of tamoxifen: intention-to-treat analysis of the
National Surgical Adjuvant Breast and Bowel project
B-33 trial. J Clin Oncol 2008; 26: 1965-71
Mauri D, Pavlidis N, Ioannidis JPA. Neoadjuvant versus
adjuvant systemic treatment in breast cancer: a
meta-analysis. J Natl Cancer Inst 2005; 97: 188-94
Perez EA, Suman VJ, Davidson N, et al. NCCTG
N9831, May 2005 update. Presented at the 45 th annual
meeting of the American Society of Clinical Oncology,
Orlando, FL, May 16, 2005
Perez EA, Suman VJ, Davidson NE, et al. Cardiac
safety analysis of doxorubicin and cyclophosphamide
followed by paclitaxel with or without trastuzumab in
the North Central Cancer Treatment Group N9831
adjuvant breast cancer trial. J Clin Oncol 2008; 26:
1231-8
Poortmans P. Evidence based radiation oncology: breast
cancer. Radiother Oncol 2007; 84: 84-101
Ravdin PM, Cronin KA, Howlader N, et al. The decrease
in breast-cancer incidence in 2003 in the United
States. New Engl J Med 2007; 356: 1670-4
Recht A, Edge SB, Solin LJ, et al. Postmastectomy radiotherapy.
Guidelines of the American Society of
Clinical Oncology. J Clin Oncol 2001; 19: 1539-69
Romond E, Perez EA, Bryant J, et al. Trastuzumab plus
Adjuvant Chemotherapy for Operable HER2-Positive
Breast Cancer. N Engl J Med 2005; 353: 1673-84
Schroth W, Antoniadou L, Fritz P, et al. Breast cancer
treatment outcome with adjuvant tamoxifen relative
to patient CYP2D6 and CYP2C19 genotypes. J Clin
Oncol 2007; 25: 5187-93
Slamon D, Eiermann W, Robert N, et al. BCIRG 006:
2 nd interim analysis phase III randomized trial comparing
doxorubicin and cyclophosphamide followed by docetaxel
(AC T) with doxorubicin and cyclophosphamide followed
by docetaxel and trastuzumab (AC TH) with docetaxel
and carboplatin and trastuzumab (TCH) in HER neu
positive early breast cancer patients. Breast Cancer Res
and Treat 2006; 100 (Suppl. 1) (abstract 52)
Smith IE, Dowsett M, Yap Y-S, et al. Adjuvant aromatase
inhibitors for early breast cancer after
chemotherapy-induced amenorrhoea: caution and suggested
guidelines. J Clin Oncol 2006; 24: 2444-7
The Breast International Group (BIG) 1-98 Collaborative
Group. A Comparison of Letrozole and Tamoxifen
in Postmenopausal Women with Early Breast Cancer.
N Engl J Med 2005; 353: 2747-57
Venturing M, Del Mastro L, Aitini E, et al. Dosedense
adjuvant chemotherapy in early breast cancer
patients: results from a randomized trial. J Natl Cancer
Inst 2005; 97: 1724-33
Zannetti R, Gafà L, Pannelli F, et al. Cancer in Italy
1993-1998: incidence data from cancer registries. Third
Volume. Roma: Il Pensiero Scientifico Editore, 2002
45